Lung cancer

TRACON to Report Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 15, 2022

Retrieved on: 
Friday, March 4, 2022
Risk, Cancer, CD73, Lung cancer, Webcast, Sarcoma, TRACON, CRO, Broadcasting, Fine chemical

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform.

Key Points: 
  • TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform.
  • TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization.
  • In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States.
  • To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com .

NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Thursday, March 3, 2022
Omicron, Society, Security (finance), Breast cancer, Interim, Director, Eli Lilly, CLIA, Program, Yale University, Leukemia, Board, COVID-19, Society for Immunotherapy of Cancer, Annual general meeting, U.S. Securities and Exchange Commission, Frontiers, Biopharmaceutical, Private Securities Litigation Reform Act, Acute myeloid leukemia, Forward-looking statement, Hope, SEC, Head, Clinical trial, Jazz Pharmaceuticals, Lung cancer, Neck, Public expenditure, Research, B cell, ASH, Partner, Survival, Sale, Marketing, SITC, IND, TME, Form 10-K, Patient, Safety, Combined, Cancer, Immunotherapy, AML, Amend, Tumor microenvironment, GLOBE, Medicine, Pharmaceutical industry, Medical imaging, Vaccine, Immunology, S15

(Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2021 financial results and provided a business update.

Key Points: 
  • (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2021 financial results and provided a business update.
  • Additionally, we expect our year-end cash position of $219.6 million to fund us into the first quarter of 2024.
  • NC318 Phase 2 update: fourth quarter of 2022 (Amended Phase 2: S15+ selection with CLIA assay, 800 mg dosed Q1W).
  • Financial Results for Fourth Quarter and Full Year EndedDecember 31, 2021
    Cash, cash equivalents, and marketable securities, excluding restricted cash as ofDecember 31, 2021, were$219.6 millionas compared with$283.4 millionas ofDecember 31, 2020.

Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

Retrieved on: 
Wednesday, March 2, 2022
Diamond, MAP, Cancer, M26 Modular Accessory Shotgun System, NEW, Conference, Lung cancer, Patient, Drug discovery, Nasdaq, Black Diamond, GLOBE, Pharmaceutical industry

Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies.

Key Points: 
  • Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies.
  • Black Diamond is addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers who have limited treatment options.
  • Black Diamond is built upon a deep understanding of cancer genetics, onco-protein function, and drug discovery.
  • Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com .

Worldwide Air Quality Monitoring Industry to 2027 - Featuring Thermo Fisher Scientific, Siemens and 3M Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, March 4, 2022
Other Health, General Health, Consumer, Technology, Environment, Construction & Property, Other Consumer, Chemicals, Plastics, Building Systems, Other Technology, Manufacturing, Health, Asthma, Particulates, Carbon monoxide, COVID-19, Organic compound, Sleep-related breathing disorder, Environment, Chronic obstructive pulmonary disease, Sulfur dioxide, Lung cancer, Air pollution, Health, Awareness, Research, Growth, Industry, Nitrous oxide, Coal, Recycling, Oil, Potash

They depend on air quality monitors to examine dispersion, dry deposition and chemical transformation and monitor deviation from the air quality standards.

Key Points: 
  • They depend on air quality monitors to examine dispersion, dry deposition and chemical transformation and monitor deviation from the air quality standards.
  • They are also implementing strategies to monitor and improve the overall air quality which, in turn, is impelling the growth of the global air quality monitoring market.
  • What is the structure of the global air quality monitoring industry and who are the key players?
  • What are the profit margins in the global air quality monitoring industry?

Global $5.85+ Bn Nuclear Imaging Equipment Markets, Competition Forecast and Opportunities, 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 4, 2022
Radiology, Health, Medical Devices, Diagnosis, Patient, Investment, Research, Conditional sentence, Prevalence, Breast cancer, Growth, Cancer, Application, Great Peace March for Global Nuclear Disarmament, CAGR, Cardiology, Lung cancer, Neurology, Medical imaging, Renewable energy, Lithium

The "Global Nuclear Imaging Equipment Market, By Product Type (PET Imaging Systems, Gamma Camera Imaging Systems), By Gamma Camera Imaging Systems, By Application, By End User, By Region, Competition Forecast and Opportunity, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Nuclear Imaging Equipment Market, By Product Type (PET Imaging Systems, Gamma Camera Imaging Systems), By Gamma Camera Imaging Systems, By Application, By End User, By Region, Competition Forecast and Opportunity, 2026" report has been added to ResearchAndMarkets.com's offering.
  • Nuclear imaging is much more efficient method for diagnosis of various life-threatening diseases thus supporting the demands of the equipment and growth of the Global Nuclear Imaging Equipment Market in the next five years.
  • To estimate and forecast the market size of the Global Nuclear Imaging Equipment Market from 2020 to 2021 and growth rate until 2026.
  • To classify and forecast the Global Nuclear Imaging Equipment Market based on product type, application, end-user, company, and regional distribution.

Median Technologies Files FDA 513(g) Regulatory Submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

Retrieved on: 
Thursday, March 3, 2022
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, Diagnosis, Medical device, BPI, Adoption, Patient, HCC, Liver cancer, De novo synthesis, LCS, Cirrhosis, Cade, Lists of diseases, Prognosis, Cave rescue, FDA, Solution, Precision medicine, Artificial intelligence, Calendar, Cancer, Technology, SME, Lung cancer screening, NASH, CEO, Data science, De novo, AI, Lung cancer, Classification, Software, DS, Medical imaging

Median Technologies (ALMDT) announces today that the company has filed a 513(g) submission on Feb. 17, 2022 to the United States Food and Drug Administration (FDA) for its iBiopsy Lung Cancer Screening (LCS) AI/ML technology-based end-to-end CADe/CADx1 Software as Medical Device (SaMD).

Key Points: 
  • Median Technologies (ALMDT) announces today that the company has filed a 513(g) submission on Feb. 17, 2022 to the United States Food and Drug Administration (FDA) for its iBiopsy Lung Cancer Screening (LCS) AI/ML technology-based end-to-end CADe/CADx1 Software as Medical Device (SaMD).
  • The 513(g) submission will allow Median Technologies to determine the best product classification and choose between the De Novo or the 510(k) regulatory pathways for iBiopsy LCS CADe/CADx SaMD.
  • Lung cancer is the deadliest cancer, and being able to detect it very early is of critical importance for patients.
  • About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

Biodesix Announces Impactful Clinical Data on the Primary Immune Response (PIR) Test at the IASLC 2022 Therapies of Lung Cancer Meeting

Retrieved on: 
Thursday, March 3, 2022
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Risk, Private Securities Litigation Reform Act, Intelligence, Annual report, Patient, MBA, Survival, Immunotherapy, Degenerative disease, Machine learning, MPH, Forward-looking statement, ICI, Biotechnology, Feinberg School of Medicine, Elgin Mental Health Center, Blood, Mass spectrometry, Large-cell lung carcinoma, Targeted molecular therapy for neuroblastoma, Artificial intelligence, Company, PIR, COVID-19, Cancer, Ira Pastan, ICIS, CEO, Diagnosis, GenScript Biotech, Potential, Malignancy, Lung, Lung cancer, Physician, Triage, Nasdaq, Form 10-K, Pharmaceutical industry, MD

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting.

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting.
  • In this body of work, the PIR test provided two classifications of PIR-Not Resistant and PIR-Resistant predictive of likely response to immune checkpoint inhibitors (ICIs).
  • This data is meaningful for patients with non-small cell lung cancer who are being considered for treatment with ICIs.
  • Immune Checkpoint inhibitor drugs have gained interest in oncology because of their ability to boost a persons immune response against cancer cells.

Known Medicine Partners with Duke University to Predict Lung Cancer Response to Drug Treatments

Retrieved on: 
Thursday, March 3, 2022
Other Health, Nanotechnology, Other Science, Pharmaceutical, Other Technology, Research, Oncology, Hospitals, Genetics, Data Management, Science, Technology, Clinical Trials, Biotechnology, Surgery, Health, University, Education, Associate, Malignant pleural effusion, Patient, Data, Machine learning, MPH, Twitter, Biotechnology, Doctor of Philosophy, LinkedIn, Duke, Cancer, Health, CEO, Duke University, Cell, Partnership, Lung cancer, Pharmaceutical industry, Medical imaging, Medicine, MD

Known Medicine, a rising biotechnology powerhouse aimed to discover new cancer drugs, announced a partnership with Duke University to predict drug efficacy for lung cancer patients.

Key Points: 
  • Known Medicine, a rising biotechnology powerhouse aimed to discover new cancer drugs, announced a partnership with Duke University to predict drug efficacy for lung cancer patients.
  • Together, Known Medicine and Duke University aim to determine if Known Medicines novel platform can be used to predict actual clinical outcomes in 75 patients.
  • We are excited to be part of the Known Medicine community and look forward to future collaborations and projects to improve patient care and treatment for lung cancer, said Mahmood, Associate Professor of Medicine at Duke.
  • Based in Salt Lake City, Utah, Known Medicine is building a predictive engine to capture patient-to-patient variability and develop the best drug for every cancer.

Global Circulating Tumor Cell Diagnostics Market to 2028 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 2, 2022
Health, Oncology, Risk, Diagnosis, Kidney cancer, Research, Patient, Cancer Research UK, Death, Industry, World, Prevalence, Breast cancer, Prognosis, Technology, Growth, Colorectal cancer, International Agency for Research on Cancer, Primary tumor, Organic, COVID-19, Lymphoma, Time, National Cancer Institute, Prostate cancer, CTC, Neoplasm, IARC, CAGR, Mortality, Seed, Lung cancer, World Health Organization, Incidence, National, Melanoma, Globe, Time-invariant system, Pharmaceutical industry, Medical imaging, Marketing, Cancer

The "Circulating Tumor Cell Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology, Application, and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Circulating Tumor Cell Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology, Application, and End User" report has been added to ResearchAndMarkets.com's offering.
  • The global circulating tumor cell (CTC) diagnostics market is projected to reach US$ 1,909.41 million by 2028 from US$ 3,656.38 million in 2021; it is expected to grow at a CAGR of 9.7% during 2021-2028.
  • A circulating tumor cell (CTC) is a cell that sheds into lymphatics from the primary tumor and carried out throughout the body with blood circulation.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the circulating tumor cell (CTC) diagnostics market.

MediFind Establishes Medical Advisory Board Led by Dr. Kyle Hogarth of University of Chicago Medicine to Further Advance Development of Consumer-Centric Health Platform

Retrieved on: 
Wednesday, March 2, 2022
Managed Care, Software, Other Health, Data Management, Oncology, Mental Health, Technology, Hospitals, Fitness & Nutrition, Cardiology, Health, Diabetes, Physical Therapy, Mathematics, Intelligence, Patient, Medical director, FCCP, Research, Chicago (franchise), University, Board, CEO, Lung cancer, MD, Physician, Publication, Algorithm, Data science, Therapy, Medical device, Bronchoscopy, Medicine

D. Kyle Hogarth, M.D., FCCP, Professor of Medicine and Director of Bronchoscopy at the University of Chicago Medicine will serve as Chief of the Medical Advisory Board.

Key Points: 
  • D. Kyle Hogarth, M.D., FCCP, Professor of Medicine and Director of Bronchoscopy at the University of Chicago Medicine will serve as Chief of the Medical Advisory Board.
  • We are thrilled to have the opportunity to work with Dr. Hogarth and the University of Chicago Medicine.
  • MediFind has built a consumer platform that leverages the power of modern computing and advanced mathematics to connect patients with world-class care.
  • D. Kyle Hogarth, MD, is a Professor of Medicine at the University of Chicago.